Platelet Integrin Alpha Iib Beta 3: Signal Transduction, Regulation, And Its Therapeutic Targeting
Jiansong Huang,Xia Li,Xiaofeng Shi,Mark Zhu,Jinghan Wang,Shujuan Huang,Xin Huang,Huafeng Wang,Ling Li,Huan Deng,Yulan Zhou,Jianhua Mao,Zhangbiao Long,Zhixin Ma,Wenle Ye,Jiajia Pan,Xiaodong Xi,Jie Jin
DOI: https://doi.org/10.1186/s13045-019-0709-6
IF: 28.5
2019-01-01
Journal of Hematology & Oncology
Abstract:Integrins are a family of transmembrane glycoprotein signaling receptors that can transmit bioinformation bidirectionally across the plasma membrane. Integrin IIb3 is expressed at a high level in platelets and their progenitors, where it plays a central role in platelet functions, hemostasis, and arterial thrombosis. Integrin IIb3 also participates in cancer progression, such as tumor cell proliferation and metastasis. In resting platelets, integrin IIb3 adopts an inactive conformation. Upon agonist stimulation, the transduction of inside-out signals leads integrin IIb3 to switch from a low- to high-affinity state for fibrinogen and other ligands. Ligand binding causes integrin clustering and subsequently promotes outside-in signaling, which initiates and amplifies a range of cellular events to drive essential platelet functions such as spreading, aggregation, clot retraction, and thrombus consolidation. Regulation of the bidirectional signaling of integrin IIb3 requires the involvement of numerous interacting proteins, which associate with the cytoplasmic tails of IIb3 in particular. Integrin IIb3 and its signaling pathways are considered promising targets for antithrombotic therapy. This review describes the bidirectional signal transduction of integrin IIb3 in platelets, as well as the proteins responsible for its regulation and therapeutic agents that target integrin IIb3 and its signaling pathways.